{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019358","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.894674+00:00","generated_at":"2026-06-01T23:36:36.973522+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Calidi Biotherapeutics Q1 net loss $7.2M, cash $1.4M after $6.1M offering","bullets":["Net loss $7.2M ($0.20/share) vs $6.5M ($0.75/share) Q1 2023; R&D $2.7M, G&A $4.0M.","Cash & restricted cash $1.4M at Mar 31, 2024, down from $2.1M at Dec 31, 2023.","Closed public offering of 15.2M shares/warrants, gross proceeds $6.1M.","Will present three posters at ASCO 2024 including Phase 1 update for CLD-101 in recurrent high-grade glioma.","CEO states focus on raising additional capital and cost cutting; Phase 1 initiation with Northwestern expected Q3 2024 subject to capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019358","json":"https://secwatch.observer/filing/0001493152-24-019358.json","markdown":"https://secwatch.observer/filing/0001493152-24-019358.md","text":"https://secwatch.observer/filing/0001493152-24-019358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224019358/0001493152-24-019358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224019358/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:36:36.973522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de67849d9f3356d9ae62535ec8be5968cc550239","claim":"Calidi Biotherapeutics, Inc. reported three months ended March 31, 2024 results: net income $7.2 million, EPS $0.20 per share.","evidence_excerpt":"The company reported a net loss of $7.2 million, or $0.20 per share, for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224019358/0001493152-24-019358-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Net income","value":"$7.2 million"},{"label":"EPS","value":"$0.20 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}